BLCO logo

BAUSCH + LOMB CORP

BLCONYSE
πŸ† #950 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track BLCO
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$7.40B
Small Cap
πŸ“ˆRevenue Growth (YoY)
8.8%
Slowing
πŸ“ŠGross Margin
61.4%
High
πŸ’΅FCF Margin
3.9%
Moderate
βš–οΈP/S Ratio
1.4x
Cheap
Otter Score
88
Excellent
No chart data available for BLCO.

Trading Snapshot

Day Range
β€”
52-Week Range
$14.44 – $21.40
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
357.4M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$5.10B
Last Q Revenue
$1.38B
P/E Ratio
β€”
P/S Ratio
1.4x
EPS (TTM)
$-0.48
Dividend Yield
β€”
Dilution (1yr)
+0.7%
BLCO logo

BAUSCH + LOMB CORP

BLCO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5.1Bβ–² +6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.8%β–Ό βˆ’10.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$188Mβ–² +16.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$66Mβ–² +11.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
354.4Mβ–² +0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$5.0Bβ–Ό βˆ’$356M YoY
StockOtter Β· stockotter.space

About BAUSCH + LOMB CORP

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Excellent
88/100
Analyst data unavailable.

Latest News & Updates

News unavailable.